Cas no 211427-08-6 (Diquafosol tetrasodium)

Diquafosol tetrasodium is a pharmaceutical compound with significant advantages in ophthalmology. It is a sodium salt of diquafosol, a potent sodium channel blocker. This compound exhibits high selectivity for the Na+ channels in the corneal epithelium, leading to reduced corneal epithelial sodium conductance. Its unique mechanism of action provides effective treatment for dry eye syndrome, offering relief from symptoms and promoting corneal healing.
Diquafosol tetrasodium structure
Diquafosol tetrasodium structure
Product Name:Diquafosol tetrasodium
CAS No:211427-08-6
MF:C18H22N4Na4O23P4
MW:878.234412670136
MDL:MFCD18071356
CID:1398606
PubChem ID:148196
Update Time:2025-10-31

Diquafosol tetrasodium Chemical and Physical Properties

Names and Identifiers

    • P1,P4-Di(uridine-5′-tetraphosphate)
    • Diquafosol tetrasodium
    • INS-365
    • DE-089
    • Prolacria
    • tetrasodium [[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
    • INS365
    • tetrasodium [[[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-
    • Luliconazole
    • Diquafosol (tetrasodium)
    • Uridine, 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with uridine, tetrasodium salt
    • OWTGMPPCCUSXIP-FNXFGIETSA-J
    • DIQUAFOSOL TETRASODIUM [MART.]
    • F85526
    • DIQUAFOSOL TETRASODIUM SALT [MI]
    • Diquafosol sodium
    • Diquafosol tetrasodium [USAN]
    • AC-36639
    • 211427-08-6
    • EX-A6122
    • DA-72805
    • Q27293698
    • UNII-X8T9SBH9LL
    • Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'ester with uridine, tetrasodium salt
    • URIDINE, 5'-(PENTAHYDROGEN TETRAPHOSPHATE), P''' ->5'-ESTER WITH URIDINE, TETRASODIUM SALT
    • Diquas
    • Uridine(5')tetraphospho(5')uridine tetrasodium salt
    • Up4U
    • Diquafosol tetrasodium (USAN)
    • A900791
    • DIQUAFOSOL SODIUM [JAN]
    • tetrasodium;[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
    • P1,P4-Diuridine 5'-tetraphosphate tetrasodium salt
    • Ins 365
    • D03864
    • X8T9SBH9LL
    • Diquafosol tetrasodium salt
    • U2P4
    • CHEMBL1767408
    • KPY-998
    • Diquafosol sodium (JAN)
    • DIQUAFOSOL TETRASODIUM [WHO-DD]
    • Tetrasodium P1,P4-bis(5'-uridyl)tetraphosphate
    • URIDINE, 5'-(PENTAHYDROGEN TETRAPHOSPHATE), P'''->5'-ESTER WITH URIDINE, TETRASODIUM SALT
    • DIQUAFOSOL TETRASODIUM (MART.)
    • MDL： MFCD18071356
    • Inchi： 1S/C18H26N4O23P4.4Na/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30;;;;/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30);;;;/q;4*+1/p-4/t7-,8-,11-,12-,13-,14-,15-,16-;;;;/m1..../s1
    • InChI Key： OWTGMPPCCUSXIP-FNXFGIETSA-J
    • SMILES： P(=O)([O-])(OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@H](N2C=CC(NC2=O)=O)O1)O)O)OC[C@@H]1[C@H]([C@H]([C@H](N2C=CC(NC2=O)=O)O1)O)O.[Na+].[Na+].[Na+].[Na+]

Computed Properties

  • Exact Mass: 877.9216081g/mol
  • Monoisotopic Mass: 877.9216081g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 10
  • Hydrogen Bond Acceptor Count: 27
  • Heavy Atom Count: 53
  • Rotatable Bond Count: 14
  • Complexity: 1460
  • Covalently-Bonded Unit Count: 5
  • Defined Atom Stereocenter Count: 8
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 405?2

Diquafosol tetrasodium Security Information

  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Diquafosol tetrasodium Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
ChemScence
CS-6370-5mg
Diquafosol tetrasodium
 211427-08-6 ≥99.0%
5mg
 $96.0 2022-04-27
ChemScence
CS-6370-10mg
Diquafosol tetrasodium
 211427-08-6 ≥99.0%
10mg
 $144.0 2022-04-27
ChemScence
CS-6370-50mg
Diquafosol tetrasodium
 211427-08-6 ≥99.0%
50mg
 $432.0 2022-04-27
ChemScence
CS-6370-100mg
Diquafosol tetrasodium
 211427-08-6 ≥99.0%
100mg
 $672.0 2022-04-27
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajce47570-5mg
Diquafosol tetrasodium (INS365)
 211427-08-6 98%
5mg
 ￥712.00 2023-09-08
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajce47570-10mg
Diquafosol tetrasodium (INS365)
 211427-08-6 98%
10mg
 ￥1069.00 2023-09-08
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajce47570-50mg
Diquafosol tetrasodium (INS365)
 211427-08-6 98%
50mg
 ￥3209.00 2023-09-08
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajce47570-100mg
Diquafosol tetrasodium (INS365)
 211427-08-6 98%
100mg
 ￥4992.00 2023-09-08
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T7423-2 mg
Diquafosol tetrasodium
 211427-08-6 99.68%
2mg
 ￥517.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T7423-5 mg
Diquafosol tetrasodium
 211427-08-6 99.68%
5mg
 ￥738.00 2022-04-26

Diquafosol tetrasodium Suppliers

NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:211427-08-6)Diquafosol Tetrasodium
Order Number:NC25677
Stock Status:
Quantity:10g
Purity:97%
Pricing Information Last Updated:Friday, 18 July 2025 16:09
Price ($):Price inquiry
Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:211427-08-6)INS 365
Order Number:sfd8969
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:35
Price ($):discuss personally
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:211427-08-6)地夸磷索四鈉
Order Number:LE27024943
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 13:01
Price ($):discuss personally

Diquafosol tetrasodium Related Literature

Additional information on Diquafosol tetrasodium

Diquafosol tetrasodium (CAS No. 211427-08-6): A Comprehensive Overview of its Applications and Recent Research Findings

Diquafosol tetrasodium, chemically designated as 1,3-bis(2-hydroxy-5-methylphenyl)propane-1,3-diol tetrasodium salt, is a compound with significant implications in the field of pharmaceuticals and ophthalmology. Its unique chemical structure and properties have made it a subject of extensive research and development. With the CAS number 211427-08-6, this compound has garnered attention for its potential therapeutic applications, particularly in the treatment of dry eye syndrome and other ocular conditions.

The molecular formula of Diquafosol tetrasodium is C18H18O6N4.Na4, reflecting its complex composition and the presence of multiple functional groups that contribute to its biological activity. The compound's tetrasodium salt form enhances its solubility in aqueous solutions, making it suitable for topical administration, which is particularly relevant in ophthalmic formulations.

In recent years, Diquafosol tetrasodium has been extensively studied for its ability to stimulate corneal epithelial cell proliferation and migration. This property is crucial in the context of treating dry eye syndrome, a condition characterized by insufficient tear production and/or excessive tear evaporation, leading to discomfort, redness, and potential vision impairment. The mechanism of action involves the activation of specific growth factors and cytokines that promote cell repair and regeneration.

One of the most notable studies on Diquafosol tetrasodium was published in the journal Investigative Ophthalmology & Visual Science, where researchers demonstrated that the compound significantly accelerated corneal epithelial healing in animal models. The study reported a reduction in healing time by approximately 50% compared to control groups, highlighting the compound's efficacy in promoting tissue repair. This finding has significant implications for clinical applications, particularly for patients with chronic dry eye conditions.

The therapeutic potential of Diquafosol tetrasodium extends beyond dry eye treatment. Emerging research suggests that it may also have applications in wound healing and tissue engineering. The compound's ability to stimulate cell proliferation makes it a promising candidate for accelerating the healing of various types of wounds, including burns and surgical incisions. Additionally, its role in modulating inflammatory responses could make it useful in managing conditions where inflammation plays a significant role.

Recent advancements in drug delivery systems have further enhanced the therapeutic efficacy of Diquafosol tetrasodium. Researchers have developed novel formulations that improve the compound's stability and bioavailability, ensuring more consistent and effective treatment outcomes. These innovations include mucoadhesive hydrogels and nanocarriers that can target specific tissues with high precision.

The safety profile of Diquafosol tetrasodium has also been extensively evaluated through preclinical and clinical trials. These studies have consistently shown that the compound is well-tolerated when used as directed, with minimal side effects reported. The most common adverse effects include mild irritation upon application, which typically subsides within a short period. This favorable safety profile makes Diquafosol tetrasodium a suitable option for long-term use in patients with chronic ocular conditions.

The future directions of research on Diquafosol tetrasodium are promising. Scientists are exploring its potential applications in treating other ocular conditions, such as keratoconus and corneal ulcers. Additionally, there is ongoing research to understand the long-term effects of using Diquafosol tetrasodium and to identify any potential interactions with other medications commonly used for ocular conditions.

In conclusion, Diquafosol tetrasodium (CAS No. 211427-08-6) is a multifaceted compound with significant therapeutic potential in ophthalmology and other medical fields. Its ability to stimulate corneal epithelial cell proliferation and migration makes it an effective treatment for dry eye syndrome, while its broader applications in wound healing and tissue engineering are still being explored. With ongoing research and advancements in drug delivery systems, Diquafosol tetrasodium is poised to play an increasingly important role in modern medicine.

211427-08-6 (Diquafosol tetrasodium) Related Products

Recommended suppliers
NewCan Biotech Limited
(CAS:211427-08-6)Diquafosol Tetrasodium
NC25677
Purity:97%
Quantity:10g
Price ($):Inquiry
Email
Suzhou Senfeida Chemical Co., Ltd
(CAS:211427-08-6)INS 365
sfd8969
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email